Editor Diary INDIA IS LIFELINE OF THE WORLD Wed, 01 May, 2019 Mohd Shahbaz Alam Trump over and again creates buzz of false nationalist to grab the media coverage. It is trend now globally, politicians talk in all front without validated data. We strongly disagree with the observations made by USTR that India and China are involved in manufacturing substandard generic medicine. USTR is The Office of the United States Trade Representative is the United States government agency responsible for developing and recommending United States trade policy to the President of the United States.
Editor Diary Singham Regulators Made Pharma India a Global Super Power But.... Sat, 20 Apr, 2019 Mohd Shahbaz Alam It is an old adage “Rome was not built in a day “Similarly global super power tag not attached to Indian Pharma Industries in a day. Regulators worked day and night in policy making, implementation and coordination with industry and global regulatory agencies for better administration. Two Singham, Dr.Surender Singh & Dr.G.N.Singh made CDSCO proactive and stronger in terms of transparency and administration.
Editor Diary FREQUENT POLICY CHANGE MEANS NATIONAL LOSS Fri, 01 Mar, 2019 EXCLUSIVE PHARMA Honourable regulators, legal advisors and manufacturers please justify as why stability is mandatory to get product permission whether old drug or a new drug. Sharing facts and asking questions as why it so happening into the pharmaceutical industry over and again. Drug and Cosmetic Act is in place to regulate the pharmaceutical industry then why everyday new circular is coming to the industry people.
Editor Diary Business career in Indian E-Pharmacy Mon, 18 Feb, 2019 EXCLUSIVE PHARMA E-pharmacies are recent entrants in the Indian e-commerce industry landscape, with it receiving increased attention from government and investors in the last three to five years. Today, the E-pharmacy market potential is worth over a 3,500 Crore with more than 35 startups assisting the growth of this segment in various regions of India. Inspite of being a novel segment in the Indian E - commerce industry, it is anticipated to grow at a CAGR of over 20%, crossing the 25,000 Cr mark by 2022.